|
Abstract:
|
[eng] Background and objective: This study aims to compare the effects of two different anti-VEGF drugs, aflibercept and ranibizumab, on OCT findings in patients with AMD. Materials and methods: We reviewed the medical records of patients diagnosed with wet type AMD between 2013-2020, who were treated with intravitreal ranibizumab or aflibercept, and had a minimum follow-up period of six months. Results: Aflibercept was injected into 50 eyes and ranibizumab was injected into 53 eyes. In best corrected visual acuity (BCVA) measurements, aflibercept was found to be superior especially at 1 month (p=0.003), and no difference was found in BCVA at 6 months (p=0.233). A negative correlation was found between BCVA measurements and SFC measurements at 1 month (r=-0.322, p=0.001). In the comparison of aflibercept and ranibizumab at 6 months; Aflibercept was found to be more effective than ranibizumab in reducing CFT (p=0.014). However, no statistically significant difference was found between aflibercept and ranibizumab in horizontal PED, vertical PED, HRD, IRC, SRF, ERM, ELM, ISOS, and CNVM measurements (p=0.119; p=0.220; p=0.167; p=0.531; p=0.351; p=0.844; p=0.768; p=0.944; p=0.703, respectively). Conclusions: Intravitreal aflibercept and ranibizumab injections in wet AMD patients were found to have similar effects on other OCT findings except for CFT. Studies with long follow-up and large series on this subject will provide more information. ; [spa] Antecedentes y objetivo: Este estudio tiene como objetivo comparar efectos de diferentes fármacos anti-VEGF, aflibercept y ranibizumab, en los hallazgos de la tomografía de coherencia óptica (OCT) en pacientes con DMAE. Materiales y métodos: Se revisaron registros médicos de pacientes diagnosticados con DMAE húmeda 2013-2020, que fueron tratados con inyecciones intravítreas de ranibizumab o aflibercept,y tuvieron un período de seguimiento mínimo de seis meses. Resultados: Aflibercept se inyectó en 50 ojos y ranibizumab en 53 ojos. En mediciones de BCVA, aflibercept demostró ser superior, especialmente a 1 mes (p=0.003), y no se encontró diferencia en BCVA 6 meses(p=0.233). Se encontró una correlación negativa entre las mediciones de BCVA y mediciones de SFC a 1 mes(r=-0.322,p=0.001). En la comparación de aflibercept y ranibizumab a 6 meses; se encontró que aflibercept era más efectivo que ranibizumab en reducir CFT(p=0.014). Sin embargo, no se encontró diferencia estadísticamente significativa entre el aflibercept y el ranibizumab en las mediciones de PED horizontal, PED vertical, HRD,IRC,SRF,ERM,ELM,ISOS y CNVM(p=0.119; p=0.220; p=0.167; p=0.531; p=0.351; p=0.844; p=0.768; p=0.944; p=0.703, respectivamente). Conclusiones: Inyecciones intravítreas de aflibercept y ranibizumab en pacientes con DMAE húmeda se encontraron tener efectos similares en otros hallazgos de OCT excepto para CFT. Estudios con seguimiento a largo plazo y grandes series sobre este tema proporcionarán más información. |
The effects of Aflibercept and Ranibizumab in patients with wet-type age-related macula degeneration